Oncology – Breast
ASCO Guideline Update: Systemic therapy for advanced human epidermal growth factor receptor 2–positive breast cancer.
1 Jun, 2022 | 11:38h | UTC
Commentary on Twitter
Out on JCO the latest @ASCO Guidelines Update on the treatment of HER2-positive ABC. Key points: standard first line remains THP, new second line is T-DXd, no standard after progression to T-DXd, a setting for which we urgently need data.https://t.co/2mMxBLACmf pic.twitter.com/2sXpzqz4ym
— Paolo Tarantino (@PTarantinoMD) June 1, 2022
ASCO Guideline Update: Management of advanced human epidermal growth factor receptor 2–positive breast cancer and brain metastases.
1 Jun, 2022 | 11:36h | UTC
Commentary on Twitter
🚨 Just published in #JCO: Guideline update on management of advanced human epidermal growth factor receptor 2–positive #breastcancer and #brainmetastases.
Read more ➡️ https://t.co/fz0lfJE8zb #bcsm #btsm #brainmets pic.twitter.com/C7tyCsVGR7
— Journal of Clinical Oncology (@JCO_ASCO) May 31, 2022
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.
31 May, 2022 | 10:46h | UTC
Commentary on Twitter
Online Now: Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies https://t.co/Im8F60VMjO
— Cancer Cell (@Cancer_Cell) May 27, 2022
RCT: Effect of supine vs. prone breast radiotherapy on acute toxic effects of the skin among women with large breast size.
27 May, 2022 | 11:51h | UTCEffect of Supine vs Prone Breast Radiotherapy on Acute Toxic Effects of the Skin Among Women With Large Breast Size: A Randomized Clinical Trial – JAMA Oncology (free for a limited period)
Editorial: Prone Whole-Breast Radiotherapy—Better Than Supine? (free for a limited period)
Commentary on Twitter
Adjuvant breast radiotherapy in the prone position decreases acute skin toxicity in women with large breast size, as demonstrated by this multicenter randomized clinical trial. https://t.co/6Emr2Hy5KH #BCSM #RadOnc
— JAMA Oncology (@JAMAOnc) May 26, 2022
Position Paper: Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer.
26 May, 2022 | 10:42h | UTC
RCT: The addition of Metformin to standard therapy did not improve outcomes in patients with breast cancer.
25 May, 2022 | 11:49h | UTCEffect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Who Will Benefit From Metformin? – JAMA Oncology
RCT: Everolimus is not beneficial when added to adjuvant endocrine therapy in patients with high-risk hormone receptor–positive, human epidermal growth factor receptor 2–negative primary breast cancer.
25 May, 2022 | 10:57h | UTC
Commentaries on Twitter
Previously presented @myESMO VP, the #UNIRAD RCT of adjuvant everolimus in high-risk EBC is now published on @JCO_ASCO. Trial stopped for futility: everolimus didn’t improve DFS & was poorly tolerated. Large research effort answering an important question.https://t.co/wmYLWpDWTC
— Paolo Tarantino (@PTarantinoMD) May 24, 2022
Everolimus added to adjuvant ET fails to improve DFS in patients with high-risk HR+ve, HER2 neg primary breast cancer; poorly tolerated -53.4% discontinuation ratehttps://t.co/lmq2jhbhCO
— K Pavithran (@drkpavithran) May 24, 2022
RCT: Effect of Denosumab added to 2 different nab-paclitaxel regimens as neoadjuvant therapy in patients with primary breast cancer.
25 May, 2022 | 10:54h | UTCEffect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Commentary on Twitter
In a randomized clinical trial in 780 pts with #breastcancer, addition of denosumab to anthracycline/taxane-containing neoadjuvant chemotherapy with two different nab-paclitaxel schedules did not increase the pCR rate (41% vs 43% without denosumab): https://t.co/gPu6hrSp7z #bcsm
— NatureRevClinOncol (@NatRevClinOncol) May 24, 2022
RCT: Elacestrant (oral selective estrogen receptor degrader) vs. standard endocrine therapy for estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer.
20 May, 2022 | 10:55h | UTC
Mammographic breast density, benign breast disease, and subsequent breast cancer risk in 3.9 million Korean women.
19 May, 2022 | 10:51h | UTCNews Release: Density, benign disease raise risk of breast cancer – Radiological Society of North America
Hair safe study: Effects of scalp cooling on hair preservation and hair regrowth in breast cancer patients receiving chemotherapy – A prospective interventional study.
19 May, 2022 | 10:15h | UTC
Nonrandomized Controlled Trial: Clinical impact of intraoperative margin assessment in breast-conserving surgery with a novel Pegulicianine Fluorescence–guided system.
18 May, 2022 | 10:28h | UTC
Commentary on Twitter
New intraoperative margin detection technology is safe and reduces reexcision rates in patients undergoing breast conserving surgery! (include infographic) #bcsm https://t.co/NqUOhGJBo4
— JAMA Surgery (@JAMASurgery) May 11, 2022
M-A: Electronic health interventions for patients with breast cancer.
16 May, 2022 | 01:16h | UTC
RCT: Treatment with Etirinotecan pegol for patients with metastatic breast cancer and brain metastases.
13 May, 2022 | 10:51h | UTCTreatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial – JAMA Oncology (free for a limited period)
Commentary on Twitter
Treatment with etirinotecan pegol showed no statistically significant improvement in survival among patients with #BreastCancer & brain metastases, but study represents larged published study for this understudied population. https://t.co/AVKeo1BWQV #BCSM #BTSM
— JAMA Oncology (@JAMAOnc) May 12, 2022
Retrospective Cohort Study: Identification of patients with branch-duct intraductal papillary mucinous neoplasm and very low risk of cancer.
9 May, 2022 | 01:40h | UTC
Commentary on Twitter
BD-IPMN 🍇 at very low risk of cancer 🔎 how to identify patients for surveillance
🌐 Multicentre Pancreas 2000 study of @EurPancClub
⚠️ 20% develop WF/HRS at FU
🏁 80% with WF/HRS still surveilled safely👉 MOST BD IPMN will never need surgery 👈https://t.co/YPHaQd98u1 pic.twitter.com/ypglRlNR2q
— Giovanni Marchegiani (@Gio_Marchegiani) May 7, 2022
A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles.
6 May, 2022 | 10:52h | UTC
Recommendations for breast cancer screening in women with extremely dense breasts.
4 May, 2022 | 08:11h | UTC
RCT: Digital breast tomosynthesis plus synthesized mammography versus digital screening mammography for the detection of invasive breast cancer.
1 May, 2022 | 23:14h | UTCDigital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled, superiority trial – The Lancet Oncology (link to abstract – $ for full-text)
Guideline: Clinical utility of multigene profiling assays in early-stage invasive breast cancer.
1 May, 2022 | 23:06h | UTC
Endocrine therapy response and 21-Gene expression assay for therapy guidance in HR+/HER2– early breast cancer.
27 Apr, 2022 | 07:41h | UTCEndocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2– Early Breast Cancer – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary: Gene Score, Endocrine Response Can Guide Early Breast Cancer Therapy – MedPage Today (free registration required)
ASCO Guideline Update: biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer.
20 Apr, 2022 | 09:47h | UTC
ASCO Guideline Update: Use of immune checkpoint inhibitor Pembrolizumab in the treatment of high-risk, early-stage triple-negative breast cancer.
19 Apr, 2022 | 01:18h | UTC
Endocrine therapies for breast and prostate cancers: Essentials for primary care.
19 Apr, 2022 | 01:14h | UTC
Phase 2 RCT: De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer.
18 Apr, 2022 | 09:31h | UTCDe-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)
Evaluation of information theoretic network meta-analysis to rank first-line anticancer regimens for hormone receptor–positive, ERBB2-negative metastatic breast cancer.
14 Apr, 2022 | 07:48h | UTCInvited Commentary: Navigating Systemic Therapeutic Options for First-Line Metastatic Hormone Receptor–Positive, ERBB2-Negative Breast Cancer Treatment – JAMA Network Open